Prior to the massive changes and limitations brought forth by the outbreak of COVID-19, clinical trials had an outdated approach to many of their processes, with effects extending through development phases, the collection of patient data, regulatory processes and numerous others. While COVID-19 has created immense difficulties, it also forces the integration of technology and innovation, which otherwise would not have seen such an immediate uptick in demand.
FDA guidance on protecting the safety of patients suddenly has sponsors scrambling for technologies that will allow them to gather patient data without having them travel to hospitals and clinics. Many companies are also contacting IRBs for guidance on modifying protocols to better accommodate patients. I took this opportunity to speak with Donald Deieso, Ph.D., chairman and CEO of WCG, to discuss the current state of clinical trials, and where we can expect the industry to go from here.
Source: Post COVID-19 Clinical Trials Will Never Be The Same
MVG Consulting Services specializes in helping small to medium sized biotechnology and pharmaceutical companies with their clinical development programs and we can provide start-up and virtual companies with the necessary resources to begin their clinical development program.
Services include:
- Clinical Research Consulting Services
- Clinical Trial Development
- Project Rescue
- Inspection Readiness
MVG provides highly qualified clinical research professionals who seamlessly become a part of your project team. Additionally, we provide virtual companies with an entire project team that encompasses all aspects of clinical development.
We invite you to fill out the form below to learn more about how MVG Consulting can help you with your clinical devleopment needs.
